Epigenomics AG

General information

Epigenomics AG
Geneststraße 5
10829 Berlin, Berlin
Germany

Contact person: Gregory Hamilton, Chief Executive Officer
Company main phone: +49 (30) 243450
Company main fax: +49 (30) 24345555
Website: https://www.epigenomics.com

Year founded:	1998
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 36

Corporate description / mission:
Epigenomics AG is a molecular diagnostics company focused on blood-based detection of cancers using the proprietary DNA methylation technology. The company develops and markets blood-based diagnostic products across multiple cancer indications. Epigenomics' lead product, Epi proColon® is a blood-based screening test for the detection of colorectal cancer.

State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2004

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Molecular diagnostics

Primary therapeutic areas:

Neoplasms / cancer / oncology

Business model:

Manufacturer
R&D
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Physicians / doctors

Distribution:

Direct (own sales force)
Indirect (independent dealer)

Summary Products / Services / Technologies

Description of products:
Epi proColon® – Liquid biopsy test for the detection of colorectal cancer
Epi proLung® – Liquid biopsy test for lung cancer detection
Epi BiSKit

Technology used:
DNA methylation biomarker technology

Financing details

Market cap. / valuation:

EUR 6.18M